INDIVIDUAL TEST 105

Erythropoietin

Indication

Suspicion of anti-Erythropoietin (EPO) antibodies and PRCA

Sample material

Serum

• Minim. volume: 1,0 mL

Transport

• Within Sweden: room temperature
• International: cold

Method

Radioimmunoprecipitation (RIP)

Reference interval

Negative

Result

Results are reported as negative or positive.

Interpretation

Antibodies against erythropoetin (EPO) are associated with a rare side effect in treatment with recombined human erythropoietin (RHuEPO) where anti EPO antibodies causes the development of red cell aplasia (PRCA) i.e. the lack of erythropoes.

Antikroppar mot erytropoetin (EPO) associeras med en mycket sällsynt biverkning vid behandling med rekombinant humant erytropoietin (rHuEPO) där anti-EPO antikroppar orsakar utveckling av pure red cell aplasia (PRCA) dvs. avsaknad av erytropoes.

References

• Thorpe R, Swanson SJ. Nephrol Dial Transplant. 2005. Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. PMID: 15827053
• Evens AM et al. Best Pract Res Clin Haematol. 2005. Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. PMID: 15792923
• Jelkmann W. Expert Opin Biol Ther. 2012. Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments. PMID: 22471247

Last updated: 2025-12-05